lorigerlimab
lorigerlimab: developed by 1 company · 7 clinical trials tracked.
lorigerlimab evidence translation
What we can confirm
7 tracked trials
What it means
What to watch
Prepared research question
How could lorigerlimab → MGNX affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| MACROGENICS INC (MGNX) Platinum-resistant Ovarian Cancer; Squamous Cell Non Small C… | Phase 2 |
Clinical Trials (7)
Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]
Primary endpoint: Safety and adverse events (AEs)
Phase II Trial of Regorafenib Plus Lorigerlimab in Patients With Locally Recurrent or Regrowing pMMR/MSS Localized Rectal Cancer
Primary endpoint: Safety and Adverse Events (AEs)
A Phase 2 Multicohort Study to Evaluate Lorigerlimab in Participants With Advanced Solid Tumors
Primary endpoint: Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria as determined by the investigator
A Phase 2, Randomized, Open-Label, Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer
Primary endpoint: Median radiographic progression free survival (rPFS) determined by investigator review.
Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION)
Primary endpoint: To establish overall survival (OS)
A Phase 1/1b Dose Escalation and Cohort Expansion Study of MGC018 in Combination With Checkpoint Inhibitor in Participants With Advanced Solid Tumors
Primary endpoint: Number of participants with adverse events (AEs)
A Phase 1, First-in-Human, Open-Label, Dose Escalation and Cohort Expansion Study of MGD019, a Bispecific DART® Protein Binding PD-1 and CTLA-4 in Patients With Unresectable or Metastatic Neoplasms
Primary endpoint: Incidence of treatment-emergent adverse events
Frequently asked questions
Who is developing lorigerlimab?
lorigerlimab is being developed by MACROGENICS INC.
How many clinical trials involve lorigerlimab?
BioSniper tracks 7 clinical trials involving lorigerlimab.